Source: Citybizlist

Zogenix: UCB Acquires Zogenix

UCB (Euronext: UCB) today announced the successful completion of the previously announced transaction to acquire Zogenix (NASDAQ: ZGNX) for US$ 26.00 per share plus... Read MoreThe post UCB Acquires Zogenix appeared first on citybiz.

Read full article »

Zogenix's Competitors | Zogenix's News | Zogenix's Financials

Followers on Owler

222

Est. Annual Revenue

$25-100M

Est. Employees

250-500

President & CEO

Stephen J. Farr

CEO Approval Rating

84/100

Zogenix is a California-based biopharmaceutical company that develops and commercializes transformative therapies for the treatment of epilepsy and mitochondrial diseases.